Hancock Whitney Corp Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)

Hancock Whitney Corp decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,139 shares of the biotechnology company’s stock after selling 62 shares during the quarter. Hancock Whitney Corp’s holdings in United Therapeutics were worth $1,842,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. Comerica Bank grew its stake in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares during the period. Tri Locum Partners LP purchased a new stake in United Therapeutics during the 2nd quarter valued at $15,959,000. QRG Capital Management Inc. lifted its holdings in shares of United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after buying an additional 1,692 shares during the period. Renaissance Technologies LLC boosted its stake in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after buying an additional 22,978 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its holdings in shares of United Therapeutics by 90.4% in the third quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 790 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. This trade represents a 74.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 117,227 shares of company stock valued at $43,671,320 in the last 90 days. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $368.66 on Tuesday. The firm has a market cap of $16.46 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The company has a 50 day simple moving average of $365.54 and a two-hundred day simple moving average of $333.04.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted $5.38 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on UTHR. Wells Fargo & Company raised their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.